Brought to you by 
Translation regulator-focused eFFECTOR Therapeutics raises $45mm through Series A round
22 May 2013
Executive Summary
Newly formed eFFECTOR Therapeutics Inc. has raised $45mm in Series A funding from US Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners, and Mission Bay Capital. US Venture, Abingworth, Novartis Venture Funds, and SR One will all take seats on the board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Translation regulator-focused eFFECTOR Therapeutics raises $45mm through Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice